FDA Patent Listing Rule Changes “Likely” To Affect Polymorphs
Executive Summary
The proposal to allow "Orange Book" listing of polymorph patents is the area "most likely" to change in FDA's upcoming Waxman/Hatch final rule, attorney and former Deputy Commissioner William Schultz predicted
You may also be interested in...
Blue Cross/Blue Shield Testing Generic Drug Ad Themes For 2003
The Blue Cross/Blue Shield Association is developing an ad campaign with the message that expanded use of generic drugs will free up resources to spend on future medical innovations
GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
The generic industry should consider carefully any attempt to derail FDA's regulatory approach to Waxman/Hatch reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association
FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims
FDA's proposed reforms to the Orange Book patent listing procedures would allow companies to list patents covering polymorphs and some types of manufacturing processes